Literature DB >> 11980952

Comparative analysis of titers of antibody against measles virus in sera of vaccinated and naturally infected Japanese individuals of different age groups.

Masae Itoh1, Yoshinobu Okuno, Hak Hotta.   

Abstract

The anti-measles virus (MV) antibody titers in the sera of vaccinees and naturally infected individuals of different age groups were measured to help assess the efficacy of the current MV vaccination in Japan. Neutralizing (NT) antibody titers induced by vaccination were 2(3.2) times lower than those induced by natural infection and declined significantly by age 20. The once-decreased NT antibody titers of the vaccinees increased 2(3.6) times during their twenties to titers comparable to those of naturally infected individuals of the same age, implying the possible occurrence of natural infection in vaccinees with decreased anti-MV immunity. Although the current field strains in Japan, types D3 and D5, were reported to differ antigenically from each other and from vaccine strains (type A) to some extent, as demonstrated by different reactivities to monoclonal antibodies, the sera of vaccinees neutralized the two types of field strains and the vaccine strain with the same efficiency. This result suggests that the current vaccine strain would be suitable to elicit protection against types D3 and D5, as long as viral antigenicity is concerned. However, when compared at given hemagglutination inhibition titers, NT antibody titers of vaccinees were 2(1.1) to 2(3.2) times lower than those of naturally infected individuals, suggesting a qualitative difference(s) of anti-MV antibodies between the two groups. It should be emphasized that protective immunity induced by the one-dose vaccination currently implemented in Japan may not be strong enough to ensure lifelong immunity. A two-dose vaccination program with higher vaccination coverage needs to be considered in order to effectively control measles in Japan.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11980952      PMCID: PMC130661          DOI: 10.1128/JCM.40.5.1733-1738.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  32 in total

Review 1.  Measles virus in the CNS: the role of viral and host factors for the establishment and maintenance of a persistent infection.

Authors:  J Schneider-Schaulies; S Niewiesk; S Schneider-Schaulies; V ter Meulen
Journal:  J Neurovirol       Date:  1999-12       Impact factor: 2.643

2.  Progress toward interrupting indigenous measles transmission--Region of the Americas, January 1999-September 2000.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2000-11-03       Impact factor: 17.586

3.  Recommendations from meeting on strategies for improving global measles control, May 11-12, 2000.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2000-12-15       Impact factor: 17.586

4.  Booster vaccination with further live attenuated measles vaccine.

Authors:  J W Bass; S B Halstead; G W Fischer; J K Podgore; W R Pearl; M Schydlower; R A Wiebe; F M Ching
Journal:  JAMA       Date:  1976-01-05       Impact factor: 56.272

5.  Measles, rubella, and congenital rubella syndrome--United States and Mexico, 1997-1999.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2000-11-24       Impact factor: 17.586

6.  The role of secondary vaccine failures in measles outbreaks.

Authors:  R G Mathias; W G Meekison; T A Arcand; M T Schechter
Journal:  Am J Public Health       Date:  1989-04       Impact factor: 9.308

7.  Measurement of measles virus-specific neutralizing antibodies: evaluation of the syncytium inhibition assay in comparison with the plaque reduction neutralization test.

Authors:  B J Ward; S Aouchiche; N Martel; F M Bertley; N Bautista-Lopez; B Serhir; S Ratnam
Journal:  Diagn Microbiol Infect Dis       Date:  1999-03       Impact factor: 2.803

8.  Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months.

Authors:  H Gans; L Yasukawa; M Rinki; R DeHovitz; B Forghani; J Beeler; S Audet; Y Maldonado; A M Arvin
Journal:  J Infect Dis       Date:  2001-08-22       Impact factor: 5.226

9.  Single genotype of measles virus is dominant whereas several genotypes of mumps virus are co-circulating.

Authors:  M Takahashi; T Nakayama; Y Kashiwagi; T Takami; S Sonoda; T Yamanaka; H Ochiai; T Ihara; T Tajima
Journal:  J Med Virol       Date:  2000-10       Impact factor: 2.327

10.  Impact of revaccinating children who initially received measles vaccine before 10 months of age.

Authors:  H C Stetler; W A Orenstein; R H Bernier; K L Herrmann; B Sirotkin; D Hopfensperger; R Schuh; P Albrecht; A W Lievens; P A Brunell
Journal:  Pediatrics       Date:  1986-04       Impact factor: 7.124

View more
  9 in total

Review 1.  Wanted, dead or alive: new viral vaccines.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Antiviral Res       Date:  2009-09-04       Impact factor: 5.970

Review 2.  How advances in immunology provide insight into improving vaccine efficacy.

Authors:  Mark K Slifka; Ian Amanna
Journal:  Vaccine       Date:  2014-04-05       Impact factor: 3.641

3.  Measles Antibodies in Mother-Infant Dyads in Tianjin, China.

Authors:  Matthew L Boulton; Xiexiu Wang; Abram L Wagner; Ying Zhang; Bradley F Carlson; Brenda W Gillespie; Yaxing Ding
Journal:  J Infect Dis       Date:  2017-11-27       Impact factor: 5.226

4.  Serum anti-tetanus and measles antibody titres in Ugandan children aged 4 months to 6 years: implications for vaccine programme.

Authors:  Lenesha Warrener; Josephine Bwogi; Nick Andrews; Dhanraj Samuel; Theopista Kabaliisa; Henry Bukenya; Kevin Brown; Martha H Roper; David A Featherstone; David Brown
Journal:  Epidemiol Infect       Date:  2018-05-09       Impact factor: 4.434

5.  Inverse relationship between serum vitamin D level and measles antibody titer: A cross-sectional analysis of NHANES, 2001-2004.

Authors:  Yi-Hsien Chen; Wei-Ming Wang; Tung-Wei Kao; Chien-Ping Chiang; Chih-Tsung Hung; Wei-Liang Chen
Journal:  PLoS One       Date:  2018-11-30       Impact factor: 3.240

6.  Inhibition of measles virus and subacute sclerosing panencephalitis virus by RNA interference.

Authors:  Momoko Otaki; Kiyonao Sada; Hiroyasu Kadoya; Motoko Nagano-Fujii; Hak Hotta
Journal:  Antiviral Res       Date:  2006-02-13       Impact factor: 5.970

7.  Comprehensive mapping of common immunodominant epitopes in the eastern equine encephalitis virus E2 protein recognized by avian antibody responses.

Authors:  Encheng Sun; Jing Zhao; Liang Sun; Qingyuan Xu; Tao Yang; Yongli Qin; Wenshi Wang; Peng Wei; Jing Sun; Donglai Wu
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

Review 8.  The Effects of Pre-Existing Antibodies on Live-Attenuated Viral Vaccines.

Authors:  Darren Z L Mok; Kuan Rong Chan
Journal:  Viruses       Date:  2020-05-08       Impact factor: 5.048

9.  Analysis of Measles-Mumps-Rubella (MMR) Titers of Recovered COVID-19 Patients.

Authors:  Jeffrey E Gold; William H Baumgartl; Ramazan A Okyay; Warren E Licht; Paul L Fidel; Mairi C Noverr; Larry P Tilley; David J Hurley; Balázs Rada; John W Ashford
Journal:  mBio       Date:  2020-11-20       Impact factor: 7.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.